Best of Oncology West 2024

Friday, January 12, 2024

Event Type: In-person

Venue: Westin Bayshore, 1601 Bayshore Dr., Vancouver, BC V6G 2V4

Directions: Google Maps Link

Event Landscape

The Best of Oncology West will consist of the most influential oncologists from across Western Canada. This event will highlight the top 3-4 most clinically relevant achievements for 2023 across many tumour sites with a focus on Western Faculty and audience.

Learning Objectives

  1. To discuss the pivotal oncology trials presented in the different disease sites
  2. To review the current standard of care for key malignancies
  3. To discuss the current controversies in the management of specific cancers

Scientific Agenda

Learn more about scheduled presentations at Best of Oncology West 2024 in the conference agenda.

About the Faculty​

Dr. Sharlene Gill

Sharlene Gill,
BSc (Pharm), MD, MPH, MBA, FACP, FRCP(C) BC Cancer

Dr. Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a Bachelor’s of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 100 peer-reviewed publications and book chapters to her credit. Dr. Gill currently serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee, and is President-Elect for the Canadian Association of Medical Oncologists.

Dr. Daniel Heng

Dr. Daniel Heng,

Dr. Daniel Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer Agency in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the International mRCC Database Consortium (IMDC) which has created and validated the IMDC criteria (a.k.a. Heng Criteria) for prognostication in metastatic renal cell carcinoma patients. He is also the Chair of the Genitourinary Tumor Group in Calgary and the head of Medical Oncology at TBCC. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies. 

Dr. Howard Lim

Dr. Howard Lim,

Dr. Howard Lim is a medical oncologist specializing in GI oncology at BC Cancer – Vancouver.  His research interests are genomic based research, clinical trials and health policy.  He is also the Co-Lead for Implementation of Competency Based Medical Education at UBC PGME and was the medical oncology residency program director. 

Dr. Nancy Nixon

Dr. Nancy Nixon,

Dr. Nancy Nixon completed her internal medicine and medical oncology specialization training in Calgary, finishing in 2016.  In 2017, Dr. Nixon completed a clinical and research fellowship in breast cancer under the supervision of Dr. Sunil Verma.  She is currently a full time medical oncologist at the Tom Baker Cancer Centre and Assistant Professor at the University of CalgarySince 2019 she has been the Southern Alberta Tumour Team Lead for medical oncologyIn 2017 she received an Early Career Research Program Award from the Canadian Institute of Health Research, and was featured in the Alberta Cancer Foundation’s LEAP magazine for her research focusing on patient priorities in cancer research. Dr. Nixon is also involved with translational research studies at the University of Calgary examining biomarkers for tumour response to treatment and immune therapies.   

Dr. Maryam Soleimani

Dr. Soleimani,

Dr. Soleimani is a Genitourinary Medical Oncologist at BC Cancer, Vancouver Cancer Centre and a clinical assistant professor at the University of British Columbia.  

She completed her Bachelor of Science (Hon) and MD degree followed by Internal Medicine residency at the University of Alberta. She then completed Medical Oncology residency at UBC, followed by a clinical and research fellowship, with a special interest in immuno-oncology and renal cell carcinoma. She has received multiple recognitions for her academic work, including a prestigious CIHR Graduate Scholarship. 

Her research interests include VHL disease, clinical trials, translational research collaboration, and cancer care delivery. Dr. Soleimani is a member of the BC Cancer Advanced Immunotherapy Program Committee and is founder and director of the BC Cancer VHL Clinic. 

Join Us Live In Person Vancouver

Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at [email protected] for registration and sponsorship opportunities. Industry registrations will be not be accepted through the website.


​For sponsorship-related inquiries, please contact Bernadette Gregoris at [email protected].

All sales are final, refunds will not be accepted.

Please note mdBriefCase Group Inc. O/A Oncology Education cannot provide visa support for event attendees, including letters of invitation. Event attendees are solely responsible for obtaining any necessary documentation required for travel and participation in the event. No refunds shall be provided to individuals who are unable to attend.

Event Sponsors









Register Now